FDA points to liver injury with Amgen’s Tavneos
Pharmaphorum
The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Pharmaceutical Technology
Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.
Symeres and Ambagon collaborate for colorectal cancer molecules
Pharmaceutical Business Review
The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Pharmaceutical Technology
Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.
ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
Pharmaceutical Technology
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit
Pharmaceutical Technology
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarke
NHS to offer Wegovy to a million more people in England
Pharmaphorum
The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Novo hits back at rivals with cut-price Wegovy subscriptions
Pharmaphorum
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout
BioPharma Dive
The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in
Viridian tumbles on positive data for key eye drug prospect
BioPharma Dive
The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
BioSpace
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
Biogen, with $5.6B Apellis buy, builds out immunology offerings
BioPharma Dive
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab
S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD
OncLive Podcast
In today’s episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC).
Novartis, Takeda Add Hundreds to Workforce Chopping Block
BioSpace
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Biogen swoops on Apellis with $5.6bn offer
Pharmaphorum
In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.
Eli Lilly makes $7.8bn takeover play for Centessa
Pharmaphorum
Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.
Merck strikes deal with antibody discovery startup
BioPharma Dive
In an R D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.
UCB brings first therapy for rare disease TK2d to EU
Pharmaphorum
The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning.